Recently, Di Xiao, associate chief physician of the Department of Vascular Surgery at Peking Union Medical College Hospital, received an invitation from the organizers of LINC (Leipzig Interventional Course) to attend the annual LINC conference in Leipzig, Germany, on January 29, 2026, and deliver a keynote presentation. Associate Chief Physician Di Xiao is one of the principal investigators of the Phase III clinical trial for our company’s innovative gene therapy drug, “Donaperminogene Seltoplasmid Ingection.” At the LINC conference, he will give a keynote speech, comprehensively presenting the clinical research findings on “Donaperminogene Seltoplasmid Ingection” for the treatment of severe chronic limb ischemia (CLI). He will share with global vascular surgeons and peers the progress and achievements of this China-led, domestically developed innovative gene therapy drug—results that have been spearheaded by Chinese clinicians.

LINC is one of the most influential academic events in the field of interventional vascular therapy in Europe. It serves as an international platform for cutting-edge technology and scholarly exchange in the field of vascular intervention, focusing on the latest advances, technologies, and clinical research in the interventional treatment of peripheral vascular diseases. The conference is held annually in Leipzig, Germany. LINC is globally renowned for its top-notch scientific committee, rigorous abstract selection process, and unwavering focus on cutting-edge technologies and clinical evidence.

The appearance of this Donaperminogene Seltoplasmid Ingectioninjection at a top-tier international academic conference not only injects innovative vitality and depth into the event but also highlights the innovative strength of Chinese vascular surgery. We believe that the “Chinese Approach” will continue to offer an increasing number of new pathways and methods for the development of vascular surgery worldwide.

Meeting Agenda: Agenda | LINC